Last updated: August 4, 2026
Clenpiq is a ready-to-drink bowel-preparation solution containing sodium picosulfate, magnesium oxide, and citric acid. Its commercial value is tied to reduced preparation burden, palatability, low dosing volume, and predictable bowel cleansing. Excipient strategy can improve taste, chemical stability, packaging compatibility, and patient adherence without changing the active-ingredient combination or the product's core clinical positioning.
Clenpiq was approved by the U.S. Food and Drug Administration in 2017 under NDA 208658. It is marketed as a 175 mL oral solution supplied in two bottles, with each bottle containing 10 mg sodium picosulfate, 3.5 g magnesium oxide, and 12 g anhydrous citric acid.[1]
What is Clenpiq and how does its formulation work?
Clenpiq combines a stimulant laxative with an osmotic magnesium-citrate system.
| Component |
Function |
| Sodium picosulfate |
Locally converted in the colon to an active stimulant laxative |
| Magnesium oxide |
Reacts with citric acid to form magnesium citrate, an osmotic laxative |
| Anhydrous citric acid |
Acidifying component and magnesium-citrate precursor |
| Water |
Oral solution vehicle |
| Sweeteners, flavors, and preservatives |
Palatability and microbiological protection |
The formulation is supplied as a low-volume liquid, but patients must consume additional clear liquids. The label instructs patients to take two separate 175 mL bottles, with the first dose administered the evening before colonoscopy and the second dose approximately five hours before the procedure.[1]
The product's design differs from high-volume polyethylene glycol-electrolyte solutions. Clenpiq seeks to reduce the volume of the supplied bowel-preparation product, while maintaining efficacy through supplemental fluid intake.
What excipients are used in Clenpiq?
The FDA-approved labeling identifies inactive ingredients that include benzoic acid, flavoring, potassium sorbate, purified water, and sucralose.[1] These excipients support four formulation objectives: preservation, taste masking, acid-base control, and acceptable oral administration.
Preservatives
Benzoic acid and potassium sorbate provide antimicrobial protection in an aqueous product. Their effectiveness depends on pH, concentration, container closure, manufacturing controls, and the microbial challenge profile of the finished product.
The acidified environment created by citric acid can support preservative activity. That same acidity can create compatibility risks with packaging materials, closure systems, and flavor components. Any reformulation that changes pH must therefore be evaluated for preservative effectiveness rather than treated as a simple taste adjustment.
Sweetener
Sucralose reduces the perceived bitterness and acidity of the formulation. Sweetener selection has commercial importance because bowel preparations are frequently rejected or incompletely consumed because of taste, nausea, or aftertaste.
Potential alternatives include acesulfame potassium, saccharin sodium, steviol glycosides, or combinations of high-intensity sweeteners. Each alternative creates a different regulatory and technical profile involving taste, pH stability, residual flavor, tolerability, and labeling.
Flavor system
Flavoring is a significant differentiation area. Citrus, berry, tropical, and neutral profiles can alter consumer acceptance without changing the active ingredients. A flavor system must remain stable in an acidic, mineral-containing solution and must not intensify magnesium, sulfur, or medicinal notes.
Flavor suppliers can create licensing opportunities through proprietary masking systems, encapsulated flavor technologies, or combinations that reduce lingering aftertaste. The commercial opportunity is strongest where taste improvement can be demonstrated in controlled patient-use studies.
Vehicle and water quality
Purified water is the principal vehicle. Water quality, mineral content, microbial limits, and process controls affect chemical stability and batch consistency. The product's high acid and mineral load makes water quality relevant to both assay control and appearance.
How can excipient strategy improve Clenpiq?
The highest-value formulation opportunities involve patient adherence rather than changes to pharmacological activity.
Taste masking and aftertaste reduction
A reformulated product could target:
- Lower perceived acidity
- Reduced magnesium taste
- Shorter aftertaste duration
- Lower sweetness intensity
- Better palatability at refrigerated or room temperature
- Reduced nausea associated with the first and second doses
Taste masking can use sweetener blends, flavor modulation, bitterness blockers, cooling agents, or pH adjustment. Any change must preserve the dissolution and reaction behavior of magnesium oxide and citric acid.
Preservative optimization
A preservative-reduced or preservative-free version could have commercial value for patients sensitive to benzoates or sorbates. This strategy would require a different microbiological control model, potentially involving:
- Single-use packaging
- Improved container closure integrity
- Aseptic or low-bioburden manufacturing
- Alternative antimicrobial systems
- Shorter in-use exposure
- More restrictive storage conditions
The opportunity is technically more demanding than changing flavor. It could create a differentiated product if the reformulation improves tolerability or expands use among patients with excipient sensitivities.
Packaging and dosing convenience
Clenpiq is already supplied in premeasured bottles. Packaging improvements could focus on administration accuracy and patient instructions rather than dose reduction.
Potential concepts include:
- Unit-dose cartons with integrated hydration instructions
- Calendar or time-of-procedure labeling
- Tamper-evident single-dose packaging
- Bottle designs that improve grip and pouring
- Temperature-stable packaging
- Co-packaged electrolyte or hydration products
Packaging patents may protect commercial improvements even when the active formulation is mature. The strongest claims would likely concern dose scheduling systems, packaging configurations, or administration kits rather than generic bottles.
Stability and supply-chain improvements
A formulation with improved stability could reduce waste and expand distribution. Relevant targets include:
- Longer shelf life
- Reduced color change
- Lower flavor degradation
- Improved preservative robustness
- Resistance to temperature excursions
- Compatibility with lower-cost packaging
Stability work should cover active-ingredient assay, degradation products, preservative levels, pH, microbial quality, appearance, taste, and container-closure integrity.
What formulation patents could protect a Clenpiq follow-on product?
Excipient changes can support patent protection when they produce a specific, reproducible technical result. Broad claims covering known ingredients are vulnerable to prior-art challenges. More defensible claim strategies may include:
| Patent focus |
Potential claim subject |
| Taste masking |
Specific sweetener-flavor ratios or bitterness-blocking systems |
| Stability |
Defined pH range, degradation threshold, and shelf-life performance |
| Preservative system |
Alternative preservative combination with demonstrated microbial control |
| Packaging |
Container-closure system that preserves chemical or microbial stability |
| Administration |
Dose-timing kit or co-packaged hydration regimen |
| Manufacturing |
Mixing sequence, temperature control, or in-process pH adjustment |
| Patient subgroup |
Formulation adapted for defined excipient intolerance or dietary restriction |
Patentability depends on the claimed composition and technical evidence. A formulation patent is stronger when comparative data show improved palatability, stability, preservative performance, or adherence against the marketed product.
A company should separate composition claims from process, packaging, and method-of-use claims. This creates multiple enforcement routes and reduces dependence on a single formulation patent.
When does Clenpiq lose regulatory exclusivity?
Clenpiq received FDA approval in 2017. The product's regulatory exclusivity and patent position are separate issues.
| Protection category |
Relevance to Clenpiq |
| New chemical entity exclusivity |
Unlikely to be the principal protection because the active ingredients were previously known |
| New drug application exclusivity |
May apply based on the approval basis and FDA designation |
| Three-year exclusivity |
Can apply to certain new clinical investigations supporting approval or a change |
| Orphan exclusivity |
Not generally associated with bowel-preparation products |
| Patent protection |
Depends on listed patents and non-Orange-Book formulation or manufacturing rights |
| Pediatric exclusivity |
Adds six months only if awarded under the applicable FDA program |
FDA Orange Book listings must be reviewed for the current patent numbers, expiration dates, and use codes. A reliable commercial assessment should not infer patent expiration from the approval date alone.[2]
What is the Orange Book status of Clenpiq?
Clenpiq is approved under NDA 208658. Orange Book status must be assessed through the current FDA Approved Drug Products with Therapeutic Equivalence Evaluations database, including any listed patents and exclusivity codes.[2]
For a generic applicant, the relevant questions are:
- Are patents listed for the solution formulation?
- Do the claims cover the active ingredient combination, excipients, packaging, or methods of use?
- Are the claims still enforceable?
- Does the proposed abbreviated new drug application need a Paragraph IV certification?
- Does any listed method-of-use patent require a section viii statement?
- Is FDA exclusivity still blocking approval?
A formulation patent may not prevent an applicant from developing a different excipient system. The applicant would need to demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy the applicable FDA requirements while avoiding valid patent claims.
What Paragraph IV challenges and litigation risks affect Clenpiq?
A generic Clenpiq applicant could challenge listed patents through a Paragraph IV certification. The NDA holder may then bring an infringement action under the Hatch-Waxman framework. A timely suit can trigger a statutory stay of FDA approval for up to 30 months, subject to statutory exceptions and litigation developments.[3]
The principal litigation issues would likely include:
- Claim construction for the sodium picosulfate-magnesium oxide-citric acid combination
- Anticipation and obviousness of low-volume bowel-preparation formulations
- Written description and enablement for excipient ranges
- Infringement by a proposed generic formulation
- Validity of formulation or manufacturing claims
- Orange Book listing requirements
- Scope of method-of-use claims
Public litigation status should be verified through PACER, FDA correspondence, and the Orange Book. No litigation conclusion should be drawn from a patent listing alone.
What commercial opportunities exist for Clenpiq excipients?
Pediatric and adolescent positioning
A more palatable product could support development in younger patients, although the clinical, safety, labeling, and dosing requirements would be separate from a simple excipient change. Pediatric opportunity is constrained by electrolyte balance, fluid management, and the need for age-appropriate administration instructions.
Excipient-sensitive patients
A formulation without benzoic acid, potassium sorbate, or sucralose could target patients who avoid specific excipients. This would be a niche opportunity unless supported by meaningful prescriber demand and clear labeling differentiation.
Hospital and ambulatory surgery channels
Hospitals and ambulatory surgery centers may value products that reduce incomplete preparation, procedure cancellations, nursing intervention, or patient callbacks. Commercial evidence should measure total preparation success rather than taste scores alone.
Private-label and licensing opportunities
Potential partners include:
- Specialty gastrointestinal companies
- Generic manufacturers with liquid-dose capability
- Excipient and flavor houses
- Contract development and manufacturing organizations
- Hospital-focused pharmaceutical suppliers
- Digital adherence and procedure-preparation platforms
Licensing value would increase if the partner controlled a validated taste-masking system, differentiated packaging, or a patent family covering a reformulated product. No specific Clenpiq licensing transaction should be assumed without documentary evidence from the rights holder or public transaction filings.
How strong is the Clenpiq formulation opportunity?
The commercial opportunity is moderate. The active ingredients are established, which limits exclusivity from the pharmacological combination alone. The strongest differentiation is likely to come from patient experience, stability, packaging, and manufacturing economics.
| Opportunity |
Commercial potential |
Technical difficulty |
IP potential |
| Flavor optimization |
Medium |
Medium |
Medium |
| Sweetener replacement |
Low to medium |
Low to medium |
Low to medium |
| Preservative-free product |
Medium |
High |
Medium to high |
| Improved shelf stability |
Medium |
Medium |
Medium |
| Single-use administration kit |
Medium |
Medium |
Medium |
| Pediatric formulation |
Medium to high |
High |
High |
| Lower-cost generic equivalent |
High |
Medium |
Low |
| Co-packaged hydration system |
Medium |
Medium |
Medium |
The most practical near-term strategy is a differentiated liquid formulation with improved taste, validated stability, and packaging that supports the two-dose schedule. The highest-risk strategy is a preservative-free product because microbiological control and shelf-life requirements may offset the commercial benefit.
Key Takeaways
- Clenpiq is a low-volume oral bowel preparation containing sodium picosulfate, magnesium oxide, and citric acid.
- Its listed excipients include benzoic acid, potassium sorbate, flavoring, purified water, and sucralose.
- Taste, aftertaste, nausea, and completion of the second dose are the main excipient-driven commercial targets.
- Formulation, packaging, manufacturing, and administration-method patents could protect follow-on products.
- FDA Orange Book listings, exclusivity codes, and current patent status require direct database verification.
- A Paragraph IV challenge could create a 30-month approval stay if the NDA holder timely files an infringement action.
- The most credible commercial opportunities are improved taste, preservative alternatives, stability, patient-oriented packaging, and hospital adherence economics.
- A generic product could avoid some formulation claims by using a different excipient system, subject to FDA pharmaceutical-equivalence and bioequivalence requirements.
FAQs
Can Clenpiq be reformulated without changing its active ingredients?
Yes. A developer could alter flavoring, sweeteners, preservatives, packaging, or manufacturing conditions, but the reformulated product would require appropriate FDA review and stability, quality, and performance data.
Would removing sucralose create a patentable Clenpiq product?
Not by itself. Patentability would depend on the complete formulation and whether the replacement produces an unexpected technical result, such as materially better taste, stability, or tolerability.
Is a preservative-free Clenpiq formulation commercially attractive?
It could be attractive for selected patients, but the strategy requires robust microbiological controls, container-closure validation, and shelf-life data. The development burden is materially higher than for a flavor change.
Can a generic manufacturer use different excipients from Clenpiq?
Potentially. FDA requirements for inactive ingredients, pharmaceutical equivalence, bioequivalence, labeling, and product quality still apply. Patent claims covering the reference formulation must also be evaluated.
Are biosimilars relevant to Clenpiq?
No. Clenpiq is a non-biologic small-molecule drug product. Competitive entry would occur through generic or other abbreviated drug-approval pathways, not the biosimilar pathway.
References
-
U.S. Food and Drug Administration. (2017). Clenpiq (sodium picosulfate, magnesium oxide, and anhydrous citric acid) oral solution prescribing information. NDA 208658.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (2017). Abbreviated new drug application submissions: Refuse-to-receive standards. Guidance for industry.
